Skip to main content

Investigational New Drugs

Ausgabe 3/2016

Inhalt (15 Artikel)

PRECLINICAL STUDIES

Microtubule-stabilizing properties of the avocado-derived toxins (+)-(R)-persin and (+)-(R)-tetrahydropersin in cancer cells and activity of related synthetic analogs

Jessica J. Field, Arun Kanakkanthara, Darby G. Brooke, Saptarshi Sinha, Sushila D. Pillai, William A. Denny, Alison J. Butt, John H. Miller

Open Access PHASE I STUDIES

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

Manisha H. Shah, Paul Lorigan, Mary E. R. O’Brien, Frank V. Fossella, Kathleen N. Moore, Shailender Bhatia, Maurice Kirby, Penella J. Woll

PHASE I STUDIES

Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison

Anne-Charlotte Dubbelman, Cynthia M. Nijenhuis, Robert S. Jansen, Hilde Rosing, Hitoshi Mizuo, Shinki Kawaguchi, David Critchley, Robert Shumaker, Jan H. M. Schellens, Jos H. Beijnen

PHASE I STUDIES

A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers

Andrew L. Coveler, Andrew H. Ko, Daniel V. T. Catenacci, Daniel Von Hoff, Carlos Becerra, Nancy C. Whiting, Jing Yang, Brian Wolpin

PHASE I STUDIES

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

B. Milojkovic Kerklaan, S. Slater, M. Flynn, A. Greystoke, P. O. Witteveen, M. Megui-Roelvink, F. de Vos, E. Dean, L. Reyderman, L. Ottesen, M. Ranson, M. P. J. Lolkema, R. Plummer, R. Kristeleit, T. R. J. Evans, J. H. M. Schellens

Open Access PHASE I STUDIES

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Toshio Shimizu, Takashi Seto, Fumihiko Hirai, Mitsuhiro Takenoyama, Kaname Nosaki, Junji Tsurutani, Hiroyasu Kaneda, Tsutomu Iwasa, Hisato Kawakami, Kazuo Noguchi, Takashi Shimamoto, Kazuhiko Nakagawa

PHASE II STUDIES

Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer

Shivaani Kummar, James L. Wade, Amit M. Oza, Daniel Sullivan, Alice P. Chen, David R. Gandara, Jiuping Ji, Robert J. Kinders, Lihua Wang, Deborah Allen, Geraldine O’Sullivan Coyne, Seth M. Steinberg, James H. Doroshow

Open Access REVIEW

RRx-001, A novel dinitroazetidine radiosensitizer

Bryan Oronsky, Jan Scicinski, Shoucheng Ning, Donna Peehl, Arnold Oronsky, Pedro Cabrales, Mark Bednarski, Susan Knox

REVIEW

Targeted therapies in gastric cancer treatment: where we are and where we are going

Gianluca Tomasello, Michele Ghidini, Wanda Liguigli, Margherita Ratti, Laura Toppo, Rodolfo Passalacqua

SHORT REPORT

Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease

Satomi Watanabe, Masayuki Takeda, Takayuki Takahama, Tsutomu Iwasa, Junji Tsurutani, Junko Tanizaki, Toshio Shimizu, Kazuko Sakai, Yoshitaka Wada, Noritaka Isogai, Kazuto Nishio, Kazuhiko Nakagawa

SHORT REPORT

A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib

Linda Mahjoubi, Anas Gazzah, Benjamin Besse, Ludovic Lacroix, Jean-Charles Soria

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.